What Ovation does

Ovation is a scientific data company operating a two-sided platform that combines a cloud-based Laboratory Information Management System (LIMS) for molecular diagnostic laboratories with a commercial multiomic data licensing business serving life sciences and biopharma customers. Founded in 2009 and headquartered in Portland, Maine, the company sells Ovation LIMS — a SaaS platform supporting workflows across qPCR, NGS, microarray, and mass spectrometry technologies for applications including COVID-19 testing, cancer genomics, pharmacogenomics, NIPT, and infectious disease — through direct enterprise field sales to clinical laboratories.

The company's distinctive asset is its clinicogenomic biobank of approximately 1.69 million consented samples from over 628,000 diverse U.S. patients, generated and replenished through the Ovation Research Network (ORN), a network of 21 independent clinical diagnostic laboratories that contribute remnant biospecimens and are compensated for sample use and sponsored research testing. Data assets include 30-50x whole genome sequencing, whole exome sequencing, and RNA sequencing linked to longitudinal phenotypic data from claims, EHR, and lab sources across 60+ pre-defined disease cohorts and 290+ pathogens, with tokenization via Datavant and distribution through AWS Data Exchange, Amazon Omics, and the DNAnexus Precision Health Data Cloud.

Ovation monetizes through three primary streams: (1) LIMS SaaS subscriptions (annual, quote-based) sold to molecular diagnostic labs including hospital labs, reference labs, and startups, with reported 38% throughput gains and 20-day startup implementation; (2) genomic and multiomic data licensing (subscription/per-dataset) to biopharma customers such as Moderna for applications including clinical trial site selection and biomarker discovery; and (3) research network participation payments to ORN labs. A fourth stream — consumer DNA tests and laboratory-developed tests for predicting GLP-1 therapy response, developed with PrecisionLife using a 10,000-patient dataset growing to 25,000 — is planned for H2 2026. The company is venture-backed (Borealis Ventures, StageDotO, SignalFire, Black Point Group, Madrona) with cumulative disclosed funding of approximately $34.78M, holds SOC 2 Type 1 and HIPAA certifications (2022), and operates as a private corporation following its September 2024 merger with PD Theranostics.

Name

Ovation

Legal name

Ovation IO Inc

Website

https://ovation.io

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Ovation is a scientific data company operating a cloud-based LIMS for molecular diagnostic laboratories paired with a clinicogenomic biobank of ~1.69 million samples from 628,000+ U.S. patients, licensing multiomic and pathogen data to biopharma customers and launching GLP-1 response genetic tests via PrecisionLife partnership in H2 2026.

Ownership category

akta.pro rank

Product category

Genomic Data and Laboratory Information Management Software

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular & Genomic LIMS (NGS/Bioinformatics Lab Ops) (HLACAMAC)

akta.pro secondary industries

Laboratory Information Management Systems (LIMS) (HLAGAJAA), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Laboratory Information Management Systems
• Genomic Data Licensing
• Multiomics Data Products
• Molecular Diagnostics Software
• Clinical Biobank Services

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Genomic Data Licensing: Ovation licenses its multiomic data products (whole genome sequencing, RNA sequencing, phenotypic data) to life sciences and biopharma companies for biomarker discovery, target identification, patient stratification, and drug development. Revenue is generated through data licensing fees, with datasets available for direct delivery or through partner platforms like AWS Data Exchange and DNAnexus.
2. LIMS Software Subscription: Ovation LIMS is sold as a cloud-based SaaS subscription to molecular diagnostic laboratories. The platform supports end-to-end lab operations from order entry to billing, with integrations across EMR systems, clinical interpretation platforms, and revenue cycle management tools.
3. Research Network Participation: Clinical laboratories in the Ovation Research Network receive payment for contributing remnant samples and performing research-related testing. Labs earn usage fees when their samples are used in research and payment for sponsored research testing projects.
4. GLP-1 Biomarker Tests (Future): Planned revenue stream from consumer DNA tests and laboratory-developed tests (LDTs) for predicting GLP-1 drug response, developed in partnership with PrecisionLife and expected to launch in H2 2026. Tests will be available as both direct-to-consumer products and through CLIA lab partners.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ovation provides a cloud-based Laboratory Information Management System (LIMS) purpose-built for molecular diagnostic laboratories, together with a commercial multiomics data business that licenses consented genomic, transcriptomic, and phenotypic datasets to life sciences companies for drug discovery and development. Its Ovation Research Network of 21 independent clinical labs continuously feeds consented remnant samples into a 1.6-million-sample biobank, while partnerships with AWS, DNAnexus, and Datavant enable distribution, analysis, and tokenized data linking.

Product overview

Ovation offers a cloud-based molecular Laboratory Information Management System (LIMS) as its core product, complemented by the Ovation Research Network for biospecimen contribution and a commercial Data Products division offering genomic and multiomic datasets. The LIMS platform handles end-to-end laboratory operations from order entry to billing, while the Research Network enables diagnostic labs to contribute remnant samples for research. Data Products provide research-ready genomic datasets across 60+ disease cohorts, including GLP-1-specific clinicogenomic data available for licensing. The company operates as a genomic data company providing paired multiomic data solutions to accelerate precision medicine development.

Differentiator

Problem solved

Functional benefit

Brands

• Ovation LIMS: Cloud-based Laboratory Information Management System software for molecular diagnostic laboratories
• Ovation Research Network (ORN)

Products and services

• Ovation LIMS Cloud-based Laboratory Information Management System purpose-built for molecular diagnostic laboratories. Supports end-to-end operations from order entry to final billing, with customizable workflows, EMR integrations (e.g., Epic), revenue cycle management integrations, clinical interpretation platform integrations (e.g., Fabric Genomics), real-time dashboards for sample tracking, and compatibility with qPCR, NGS, microarray, and mass spectrometry technologies. Sold as an annual SaaS subscription to clinical labs.
• Ovation Research Network Network of 21 independent, geographically and demographically diverse U.S. clinical diagnostic laboratories that contribute consented remnant biospecimens for research. Participating labs receive usage fees when their samples are used in research and payment for sponsored research-related testing, while gaining a path to participate in real-world data opportunities.
• Genomic Data Products High-quality 30-50x whole genome sequencing data sourced from consented remnant samples linked to phenotypic data from claims, EHR, and lab real-world data sources. Drawn from a biobank of 628,000+ diverse U.S. individuals, consented for research and commercial purposes. Licensed to life sciences and biopharma customers for biomarker discovery, target identification, and patient stratification. Delivered directly or via AWS Data Exchange, Amazon Omics, and DNAnexus.
• Pathogen Data Real-world pathogen testing and sequencing data covering 290+ pathogens including COVID-19, influenza, and respiratory syncytial virus. Includes viral genomic data integrated with patient clinical and demographic data, refreshed up to hourly for near-real-time surveillance. Used by life sciences customers for vaccine and therapeutic research, vaccine trial enrollment planning, and epidemiological studies (e.g., Moderna used Ovation RSV testing data for ConquerRSV trial enrollment).
• GLP-1 Clinicogenomic Dataset Disease-specific clinicogenomic dataset of 10,000 whole-genome-sequenced patients with linked longitudinal phenotypic data, developed for GLP-1 receptor agonist (semaglutide, tirzepatide) response research, patient stratification, and clinical trial enrichment. Licensed to biopharma customers on an annual subscription basis.

Quantifiable outcome

• 38% increase in sample throughput for labs using Ovation LIMS
• +7 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration15 records

AI capability5 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• PrecisionLifecoreStrategic or Co-development Partner · 15 April 2026Strategic collaboration to develop and commercialize GLP-1 response genetic tests. PrecisionLife analyzes Ovation's GLP-1 receptor agonist dataset using their AI-driven combinatorial analytics platform to identify biomarkers that predict patient response to GLP-1 therapies like semaglutide and tirzepatide. Phase 1 identified 2,500+ genetic signatures in 4,600 patients. Phase 2 expanding to 25,000 patients. Plans include consumer DNA test and LDT launch in H2 2026.
• DNAnexuscoreTechnology or Integration · 20 March 2024Partnership to deliver integrated multiomics data and analysis solutions. Ovation's IBD omics data is combined with DNAnexus Precision Health Data Cloud platform, enabling researchers to seamlessly integrate, analyze, and interpret complex biological datasets. Companies presented jointly at the 2nd Precision Medicine in IBD Summit.
• Amazon Web Services (AWS)coreTechnology or IntegrationAWS serves as the primary cloud infrastructure for Ovation's data storage and delivery. Ovation's genomic and pathogen data is available on AWS Data Exchange. The companies partner on data delivery via Amazon Omics for variant storage and analysis, with data automatically importable into data lakes using AWS Step Functions and Lake Formation.
• DatavantcoreTechnology or IntegrationPartnership for data tokenization and linking services. Datavant's common tokenization mechanisms enable Ovation to link deep genomic data to phenotypic data from claims, EHR, and lab real-world data sources. Joint webinar presented on linking genomic and phenotypic data to understand the patient journey.
• NIH RADx Tech Variant Task ForceflagshipStrategic or Co-development PartnerOvation Research Network participates in the NIH Rapid Acceleration of Diagnostics (RADx) Tech program. Ovation provides real-world pathogen surveillance data including COVID-19 variant genotyping. Results contributed to the Rosalind Tracker public dashboard. Ovation's involvement expanded the platform's geographic reach to rural and underserved populations.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Benchling: Cloud-based informatics platform serving biotech R&D and increasingly molecular diagnostic labs with structured LIMS-like workflows. Directly comparable as a SaaS lab informatics vendor pursuing biopharma customers with centralized data capture.
• DNAnexus: Multiomics data platform and Precision Health Data Cloud partner of Ovation, serving life sciences customers with genomic data storage, analysis, and cohort delivery. Directly comparable as a partner-and-occasionally-competitor in the genomic data delivery layer.
• PrecisionLife: AI-driven combinatorial analytics company co-developing GLP-1 response biomarkers with Ovation using its genomics dataset. Directly comparable as a strategic partner whose analytics layer could be applied to similar clinicogenomic assets elsewhere.
• Sapio Sciences: Cloud LIMS and lab informatics provider targeting molecular diagnostics and clinical labs with configurable workflows. Closely comparable as a similarly-sized LIMS challenger competing in the same molecular lab segment.
• MedGenome: Genomics research and diagnostics provider offering curated multiomic datasets and lab services to biopharma globally. Comparable as a competing genomic-data licensor targeting the same biomarker discovery and patient stratification buyers.
• Genuity Science: Genomic and clinical data platform offering consented cohort data and analytics services to biopharma. Comparable as a direct genomic data licensing peer with similar clinicogenomic cohort offerings.

Broad incumbents

• LabWare: Long-standing enterprise LIMS vendor with deep penetration across regulated laboratories including molecular diagnostics. Comparable as the incumbent LIMS alternative Ovation competes against for replacement and new-lab deals.
• Illumina BaseSpace Sequence Hub: Illumina's genomics cloud platform for sample-to-analysis workflows, used widely by molecular diagnostic labs and integrated with its sequencing instruments. Comparable as the dominant sequencing-adjacent informatics environment Ovation must integrate with rather than displace.
• Genedata: Enterprise bioinformatics platform for omics data management and analysis across pharma R&D and translational workflows. Comparable as a larger incumbent in life science informatics competing for similar biopharma IT budgets.

Emerging players

• Datavant: Health data tokenization and linkage platform used by Ovation to connect genomic and phenotypic data; also licenses de-identified real-world data to life sciences. Comparable as an adjacent data infrastructure peer in the same biopharma go-to-market.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ovation-io
• Xx.com/ovation_io

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ovation